MicroRNA Regulation of Insulin Resistance in Metabolic Disorders

MicroRNAs (miRNAs) are small non-coding RNA molecules that fine-tune gene expression by binding to complementary sequences in messenger RNA, leading to translational repression or degradation. In metabolic disorders such as obesity and type 2 diabetes, dysregulated miRNA networks alter key nodes of the insulin-signalling cascade across liver, muscle and adipose tissue, contributing to impaired glucose uptake, elevated gluconeogenesis and chronic inflammation. Tissue-specific miRNAs can target insulin receptor substrates, phosphatases and transcription factors to exacerbate or ameliorate insulin resistance. Emerging evidence highlights the dual roles of miRNAs as both biomarkers of metabolic dysfunction and as therapeutic candidates, with several miRNAs demonstrating conserved functions across species and potential for modulation by dietary or pharmacological interventions.

Research from Nature Portfolio

Recent studies have identified miR-19a as a pivotal regulator of hepatic insulin sensitivity through its direct repression of the phosphatase PTEN. Overexpression of miR-19a in hepatocytes enhances activation of the AKT–GSK signalling axis and promotes glycogen synthesis, while miR-19a knockdown impairs these processes. Furthermore, restoration of miR-19a levels counteracts interleukin-6-induced reductions in glycogenesis, underscoring its potential to reverse cytokine-mediated insulin resistance. This work establishes miR-19a as a foundational example of how targeting a single miRNA–mRNA interaction can recalibrate metabolic pathways.

MicroRNA Regulation of Insulin Resistance in Metabolic Disorders publication trend

The graph below shows the total number of articles in microrna regulation of insulin resistance in metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA (miRNA): A small non-coding RNA, typically 20–22 nucleotides long, that binds to the 3′ untranslated region of target mRNAs to inhibit translation or promote degradation.

Insulin resistance: A state in which target tissues such as liver, muscle or adipose exhibit a reduced response to circulating insulin, leading to impaired glucose uptake and elevated blood glucose levels.

AKT–GSK signalling pathway: A key insulin-activated kinase cascade in which AKT phosphorylates and inhibits glycogen synthase kinase (GSK), thereby promoting glycogen synthesis.

PTEN: Phosphatase and tensin homologue, a lipid phosphatase that negatively regulates the AKT pathway by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate.

LRP6: Low-density lipoprotein receptor-related protein 6, a co-receptor in Wnt signalling that influences hepatic lipid metabolism and insulin sensitivity.

Glycogenesis: The enzymatic process by which glucose is converted into glycogen for storage, primarily in liver and muscle.

References

1. MiR-19a regulates PTEN expression to mediate glycogen synthesis in hepatocytes. Scientific Reports (2015).
2. Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity. eLife (2024).
3. MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes. International Journal of Molecular Sciences (2018).
4. High-throughput sequencing of small RNAs and analysis of differentially expressed microRNAs associated with high-fat diet-induced hepatic insulin resistance in mice. Genes & Nutrition (2019).